These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 11416729)
1. Efavirenz plasma concentrations and efficiency. López-Cortés LF; de Alarcón A; Viciana P AIDS; 2001 Jun; 15(9):1192-4. PubMed ID: 11416729 [No Abstract] [Full Text] [Related]
2. Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin. Manosuthi W; Sungkanuparph S; Thakkinstian A; Vibhagool A; Kiertiburanakul S; Rattanasiri S; Prasithsirikul W; Sankote J; Mahanontharit A; Ruxrungtham K AIDS; 2005 Sep; 19(14):1481-6. PubMed ID: 16135901 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. López-Cortés LF; Ruiz-Valderas R; Viciana P; Alarcón-González A; Gómez-Mateos J; León-Jimenez E; Sarasanacenta M; López-Pua Y; Pachón J Clin Pharmacokinet; 2002; 41(9):681-90. PubMed ID: 12126459 [TBL] [Abstract][Full Text] [Related]
4. Penetration of efavirenz into the male genital tract: drug concentrations and antiviral activity in semen and blood of HIV-1-infected men. Taylor S; Reynolds H; Sabin CA; Drake SM; White DJ; Back DJ; Pillay D AIDS; 2001 Oct; 15(15):2051-3. PubMed ID: 11600838 [TBL] [Abstract][Full Text] [Related]
5. SSRI safe with efavirenz. AIDS Patient Care STDS; 2000 Dec; 14(12):672-3. PubMed ID: 11187111 [No Abstract] [Full Text] [Related]
6. A review of abacavir and efavirenz: new antiretroviral drugs to treat HIV-1 infection. Wolbach J; Capoccia K Nurse Pract; 1999 Jun; 24(6):81-2, 87-90, 92. PubMed ID: 10431297 [No Abstract] [Full Text] [Related]
7. Efavirenz plasma levels for the prediction of treatment failure in heavily pretreated HIV-1 infected patients. Langmann P; Weissbrich B; Desch S; Väth T; Schirmer D; Zilly M; Klinker H Eur J Med Res; 2002 Jul; 7(7):309-14. PubMed ID: 12176680 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy. Leth FV; Kappelhoff BS; Johnson D; Losso MH; Boron-Kaczmarska A; Saag MS; Livrozet JM; Hall DB; Leith J; Huitema AD; Wit FW; Beijnen JH; Lange JM; AIDS Res Hum Retroviruses; 2006 Mar; 22(3):232-9. PubMed ID: 16545009 [TBL] [Abstract][Full Text] [Related]
9. Complete remission of AIDS/Kaposi's sarcoma after treatment with a combination of two nucleoside reverse transcriptase inhibitors and one non-nucleoside reverse transcriptase inhibitor. Murdaca G; Campelli A; Setti M; Indiveri F; Puppo F AIDS; 2002 Jan; 16(2):304-5. PubMed ID: 11807324 [No Abstract] [Full Text] [Related]
11. [Efavirenz and nevirapine plasma levels in HIV-infected patients with hemophilia]. Martorell M; López RM; Ribera E; Ruiz I; Tural C; Puig L; Monterde J Enferm Infecc Microbiol Clin; 2005; 23(6):349-52. PubMed ID: 15970167 [TBL] [Abstract][Full Text] [Related]
12. High plasma levels of nelfinavir and efavirenz in two HIV-positive patients with hepatic disease. Maserati R; Villani P; Seminari E; Pan A; Lo Caputo S; Regazzi MB AIDS; 1999 May; 13(7):870-1. PubMed ID: 10357395 [No Abstract] [Full Text] [Related]
13. Higher efavirenz concentrations determine the response to viruses carrying non-nucleoside reverse transcriptase resistance mutations. González de Requena D; Gallego O; Corral A; Jiménez-Nácher I; Soriano V AIDS; 2004 Oct; 18(15):2091-4. PubMed ID: 15577634 [TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Csajka C; Marzolini C; Fattinger K; Décosterd LA; Fellay J; Telenti A; Biollaz J; Buclin T Clin Pharmacol Ther; 2003 Jan; 73(1):20-30. PubMed ID: 12545140 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic drug monitoring of efavirenz: trough levels cannot be estimated on the basis of earlier plasma determinations. López-Cortés LF; Ruiz-Valderas R; Marín-Niebla A; Pascual-Carrasco R; Rodríguez-Díez M; Lucero-Muñoz MJ J Acquir Immune Defic Syndr; 2005 Aug; 39(5):551-6. PubMed ID: 16044006 [TBL] [Abstract][Full Text] [Related]
16. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. Marzolini C; Telenti A; Decosterd LA; Greub G; Biollaz J; Buclin T AIDS; 2001 Jan; 15(1):71-5. PubMed ID: 11192870 [TBL] [Abstract][Full Text] [Related]
17. Efavirenz and nevirapine in HIV-1 infection : is there a role for clinical pharmacokinetic monitoring? Dahri K; Ensom MH Clin Pharmacokinet; 2007; 46(2):109-32. PubMed ID: 17253884 [TBL] [Abstract][Full Text] [Related]
18. Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors in HIV-infected children. Funk MB; Notheis G; Schuster T; Elanjkal Z; von Hentig N; Stürmer M; Linde R; Dunsch D; Königs C; Wintergerst U; Kreuz W Eur J Med Res; 2005 Dec; 10(12):503-8. PubMed ID: 16356864 [TBL] [Abstract][Full Text] [Related]
19. Clinical history of efavirenz. Ruiz N Int J Clin Pract Suppl; 1999 Jun; 103():3-7. PubMed ID: 10622035 [TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals. Kappelhoff BS; Huitema AD; Yalvaç Z; Prins JM; Mulder JW; Meenhorst PL; Beijnen JH Clin Pharmacokinet; 2005; 44(8):849-61. PubMed ID: 16029069 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]